Profile: Perrigo Company PLC (PRGO.N)
24 May 2019
Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, incorporated on June 28, 2013, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences. The Company manufactures OTC healthcare products and supplies infant formulas for the store brand market. It is also a provider of generic extended topical prescription products. It provides healthcare products across a range of product categories and geographies, primarily in North America, Europe and Australia, as well as in other markets, including Israel and China.
The Company's CHC segment is focused on the sale of OTC store brand products, including cough, cold, allergy and sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health and diagnostic products. The Company markets in various geographies, including the United States, the United Kingdom and Mexico. Its branded products include the Good Sense, Sergeant's, Sentry, Herron, PetArmor value brands, and the ScarAway brand name.
Branded Consumer Healthcare
The Company's BCH segment develops, manufactures, markets and distributes various European OTC brands in categories, such as natural health, cough, cold and allergy, personal care and derma-therapeutics, lifestyle and pain relief. In addition, the segment manages its regulatory, sales and distribution infrastructure to in-license, and sells non-owned brands and generic pharmaceutical products.
The Company's Rx segment develops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs for the United States and the United Kingdom markets. It offers a range of topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions and powders. The portfolio also includes select controlled substances, injectables, hormones, women's health products, oral solid dosage forms and oral liquid formulations. Its development areas include other delivery systems, such as oral liquids, metered dose inhalers, injectables and transdermal products. In addition, the Rx segment offers OTC products through the prescription channel (referred to as ORx, these products are marketed using the Perrigo name). ORx products are OTC products that are available for pharmacy fulfillment and healthcare reimbursement when prescribed by a physician. It offers various ORx products that are reimbursable through various health plans and the United States Medicaid and Medicare programs. It manufactures and distributes a range of generic prescription products under various brand names, including Differin, BenzaClin, Entocort, Evoclin, Duac, Olux, Olux-E, Clobex, Desonate, Tridesilon, D.H.E. 45, Ultravate, Bactroban, Mycostatin, Elimite, Klor-Con, Protopic, Androgel, Depo, Testosterone and Triderm/Kenalog.
The Company's Specialty Sciences segment consists of assets focused on the treatment of multiple sclerosis, specifically in connection with the drug, Tysabri (natalizumab). Tysabri also focused on the treatment of Crohn’s diseases.
The Company competes with LNK International, Inc., PL Developments, International Vitamin Corporation, Dr. Reddy's Labs, Johnson & Johnson, Pfizer, Bayer AG, Nestle S.A., Abbott Nutrition, NBTY, Mead Johnson Nutrition Co., Reckitt Benckiser, Boehringer Ingelheim, Novartis, Allergan plc, Apotex Corp., Glenmark Generics Inc., Impax Laboratories, Inc., Mylan N.V., Prasco, LLC, Sandoz, Sun Pharmaceuticals, Taro Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Triax Pharmaceuticals, LLC and Zydus Pharmaceuticals, Inc.
Perrigo Company PLC
The Sharp Building, Hogan Place
DUBLIN D02 TY74